Tricida upgraded by JP Morgan with a new price target
$TCDA
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan upgraded Tricida from Underweight to Neutral and set a new price target of $7.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/13/2022 | $25.00 | Buy | Goldman |
| 11/16/2021 | $7.00 | Underweight → Neutral | JP Morgan |
Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 pla
Webcast Today at 4:30 pm Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and six months ended June 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in May 2022 that it stopped its VALOR-CKD renal outcomes trial early for administrative reasons as permitted by the existing study protocol to allow for six months of financial runway following the reporting of top-line results, which is anticipated to occur in October 2022. The VALOR-CKD trial has continued to accrue primary endpoint events as clinical trial subjects complete their participation in the study which, for the last subject, is currently projected to
SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (NASDAQ:TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows: Tricida Second Quarter Financial Results Conference CallMonday, August 8, 20224:30 pm Eastern Time Webcast:IR.Tricida.com Dial-in:(800) 715-9871 International:(646) 307-1963 Conference ID:3576787 A replay of the webcast will be available on Tricida's website approximately two hours
Goldman initiated coverage of Tricida with a rating of Buy and set a new price target of $25.00
JP Morgan upgraded Tricida from Underweight to Neutral and set a new price target of $7.00
SC 13G/A - Tricida, Inc. (0001595585) (Subject)
SC 13G/A - Tricida, Inc. (0001595585) (Subject)
SC 13G/A - Tricida, Inc. (0001595585) (Subject)
EFFECT - Tricida, Inc. (0001595585) (Filer)
15-12G - Tricida, Inc. (0001595585) (Filer)
S-8 POS - Tricida, Inc. (0001595585) (Filer)
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
4 - Tricida, Inc. (0001595585) (Issuer)
Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today that Dr. Sandra Coufal, M.D. will join Toragen as its new CEO. Dr. Coufal brings over 30 years of experience to Toragen as a physician and serial entrepreneur working with multiple successful companies in medicine, chemistry, biotechnology, material sciences, and digital technology. This press release features multimedia. View the full release here: https://www.businesswire.c
Tricida, Inc. (NASDAQ:TCDA) announced today financial results for the three and nine months ended September 30, 2022 and provided an update on key initiatives. Business Update Tricida announced in October the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration
Tricida, Inc. (NASDAQ:TCDA), announced today that the Board of Directors has authorized Tricida to initiate a review of strategic alternatives to maximize stakeholder value. To facilitate this review, Tricida has engaged Stifel and its wholly owned affiliate, Miller Buckfire, to serve as investment banking advisors and SierraConstellation Partners LLC to serve as a financial advisor. This strategic review may include consideration of the sale of the Company and/or its assets. Tricida is also currently evaluating plans to reduce operating expenses and anticipates initiating and announcing these plans in November 2022. The Board of Directors and Tricida intend to conduct a thorough review of
Webcast today at 8:00 am Eastern Time Tricida, Inc. (NASDAQ:TCDA) announced today the top-line results from its VALOR-CKD renal outcomes clinical trial, designed to evaluate veverimer's ability to slow CKD progression in patients with metabolic acidosis and chronic kidney disease (CKD). Primary Endpoint Analysis The VALOR-CKD trial did not meet its primary endpoint, which was defined as the time to the first occurrence of any event in the composite endpoint of renal death, end-stage renal disease (ESRD), or a confirmed greater than or equal to 40% reduction in estimated glomerular filtration rate (eGFR), also known as DD40. One hundred forty-nine veverimer-treated patients versus 148 pla
Gainers Jaguar Health (NASDAQ:JAGX) stock rose 6215.8% to $5.35 during Monday's regular session. The current volume of 532.2K shares is 6.8% of Jaguar Health's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $808.9 million. Intelligent Bio Solutions (NASDAQ:INBS) stock increased by 424.84% to $1.38. As of 12:30 EST, Intelligent Bio Solutions's stock is trading at a volume of 115.7 million, which is 206846.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $25.2 million. Pliant Therapeutics (NASDAQ:PLRX) stock rose 46.3% to $32.93. Trading volume for this
On Monday, 12 stocks hit new 52-week lows. Noteable 52-Week Lows: Innovative Ind Props (NYSE:IIPR) was the largest, in terms of market cap, to set a new 52-week low. Tricida (NASDAQ:TCDA) was the smallest company by market cap to set a new 52-week low. Amesite (NASDAQ:AMST) saw the most pronounced move, as shares traded down 17.22% to hit its new 52-week low. Clough Global Equity (AMEX:GLQ) shares actually gained 0.16%, rebounding after it reached its 52-week low. Stocks dropping to new 52-week lows on Monday: Innovative Ind Props (NYSE:IIPR) stock broke to a new 52-week low of $87.20 on Monday. Shares of the company traded up 0.92%. Pacira BioSciences (NASDAQ:PCRX) shares ma
Friday saw 23 companies set new 52-week lows. Significant Points From Today's 52-Week Lows: L3Harris Technologies (NYSE:LHX) was the largest firm by market cap to set a new 52-week low. The smallest company on a market cap basis to set a new 52-week low was Digital Brands Group (NASDAQ:DBGI). Windtree Therapeutics (NASDAQ:WINT) saw the most pronounced move, as shares traded down 26.62% to hit its new 52-week low. Arqit Quantum (NASDAQ:ARQQ) saw the biggest bounce back on, as shares traded up 0.0% to rebound after it hit its new 52-week low. Stocks that set new 52-week lows on Friday are as follows: L3Harris Technologies (NYSE:LHX) stock set a new 52-week low of $190.11 on Frid